PFE stock​ today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest 2026 outlook. Declining Covid product sales and patent expirations are key ...

Pfizer stock tumbled early Tuesday after the drugmaker reaffirmed its modest outlook for 2026 and provided an obesity update.

Stock Market Today: Small caps join the S&P 500 and Dow in losses. Nvidia falls below this level.

Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.

Pfizer shares fell as much as 5% Tuesday morning on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and ...

Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

US equities moved lower on Tuesday as investors weighed earnings against a partial US government shutdown that has delayed key economic releases. The S&P 50 ...